VistaGen Therapeutics(US:VTGN) Prnewswire·2026-02-04 19:46Core Viewpoint - Vistagen Therapeutics, Inc. is facing a securities class action lawsuit due to alleged misleading statements regarding its clinical trial program for its lead drug candidate, with a lead plaintiff deadline set for March 16, 2026 [1][8]. Group 1: Allegations of Misleading Statements - Management allegedly created an overwhelmingly positive impression about the clinical trial program, emphasizing "notable enhancements" and "operational changes" intended to improve enrollment quality and limit variability [3]. - The company claimed that positive results from a prior Phase 3 trial, combined with operational improvements, positioned the subsequent study as a confirmatory trial with a strong likelihood of success [4]. Group 2: Omitted Risks - The complaint alleges that while promoting the trial's positive aspects, the company failed to disclose material risks inherent in the clinical trial design, specifically known issues with public speaking challenge endpoints that often show elevated placebo responses and site variability [5]. - Defendants are accused of continuing to promote the trial modifications and presenting the study as likely to succeed while concealing these known risks from investors [6].